MapLight Therapeutics, Inc. (MPLT)
D
Pipeline Grade
Financial Position (from SEC Filings)
$55.7M
Cash & Equivalents
$51.2M
Quarterly Burn Rate
3 mo
Est. Cash Runway
$1,676M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05889273 | ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD) | PHASE2 | Enrolling By Invitation | 120 |
| NCT07459647 | A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia | PHASE2 | Recruiting | 500 |
| NCT06887192 | A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis | PHASE2 | Recruiting | 300 |
| NCT07459660 | An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis | PHASE2 | Recruiting | 210 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-22 | 8-K | MapLight Therapeutics, Inc. (MPLT) (CIK 0001770069) - EX-99.1 | EDGAR |